Attention deficit hyperactivity disorder (ADHD) is a neural disorder.
The disorder is characterized by impulsiveness, hyperactivity, and
attention difficulty. Treatment of ADHD involves a combination of
counseling, medications, and lifestyle changes. ADHD is the most
commonly diagnosed mental disorder in adults and children with the
exact cause being unidentified in the majority of cases. Researchers
at the National Institute of Mental Health (NIMH) suggest the factors
affecting mental illness include heredity, brain injuries, low birth
weight, drugs use during pregnancy and exposure to environmental
toxins such, as lead at young age. The currently available
treatments, such as medication, counseling, lifestyle changes or a
combination of these treatments helps in reducing symptoms with
improved functioning of patient.
Download
PDF Brochure @
https://www.coherentmarketinsights.com/insight/request-pdf/830
Rising number of drug-treated patients for ADHD therapy is
expected to drive the attention deficit hyperactivity disorder (ADHD)
treatment market
According to the National Institute of Health estimates in 2015, the
prevalence of ADHD is higher by 30% in boys, with 5.1 million
children being diagnosed with ADHD globally in 2013 and the number
expected to rise to 18 million by 2020. Increasing awareness of ADHD
symptoms among patients and physicians, opinion-based diagnosis owing
to the absence of standard diagnostic tests is expected to boost the
revenue growth of ADHD therapeutics market in the forecast period.
Additionally, rise in the ADHD therapeutics market is driven by
increasing use of additives and preservatives in diet, value systems
impacting quality of births, and changing lifestyles. However,
restricted availability of non-stimulants ADHD drugs and existence of
multiple conditions like schizophrenia or depression in children
leads to underdiagnoses of ADHD in various geographies including
Middle East and Africa, thereby restraining the growth of the market
over the forecast period. Since Adderall abuse has grown to epidemic
levels, our research team has compiled an article about the best
all-natural alternatives to Adderall.
Drug development and market consolidation strategies fuel the
demand of some manufacturers
Key players operating the attention deficit hyperactivity disorder
(ADHD) treatment market include Eli Lilly, GlaxoSmithKline PLC,
Pfizer Inc, Novartis AG and Shire PLC. The key strategies adopted by
the manufacturers are developing cost-efficient drugs, which are safe
for consumption and market consolidations. The other key vendors
include Impax Laboratories, Hisamitsu Pharmaceutical Inc.,
Mallinckrodt Pharmaceuticals Inc., UCB S.A., Purdue Parma L.P and
Johnson & Johnson.
The non-stimulants market segment accounts for highest revenue
share owing to its efficient treatment improving focus and
impulsivity
The global attention deficit hyperactivity disorder (ADHD) treatment
market is segmented on the basis of drug type, distribution channel
and geography.
On the basis of drug type, the global attention deficit
hyperactivity disorder (ADHD) treatment market is segmented into:
• Stimulants
o Amphetamine
o Methylphenidate
o Dexmethylphenidate
o Dextroamphetamine
o Lisdexamfetamine Dimesylate
• Non-stimulants
o Atomoxetine
o Clonidine
o Guanfacine
o Bupropion
On the basis of therapy, the global attention deficit
hyperactivity disorder (ADHD) treatment market is segmented into:
• Behavior Therapy
• Cognitive Behavioral Therapy
• Interpersonal Psychotherapy
• Family Therapy
Browse
Full Exclusive Research Report at
https://www.coherentmarketinsights.com/ongoing-insight/attention-deficit-hyperactivity-disorder-treatment-market-830
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and
consulting firm offering action-ready syndicated research reports,
custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends,
technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
No comments:
Post a Comment